Preclinical cardiovascular risk assessment in modern drug development

Toxicological Sciences

Volumn 97, Issue 1, 2007, Pages 4-20

  Guth, Brian D ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; BEPRIDIL; ERYTHROMYCIN; HALOTHANE; KETAMINE; PENTOBARBITAL; PIMOZIDE; POTASSIUM CHANNEL HERG; RUBIDIUM; SEDATIVE AGENT; SOTALOL; TERFENADINE; VERAPAMIL; KCNH2 PROTEIN, HUMAN; NEW DRUG; UNCLASSIFIED DRUG;

ANESTHESIA; ARTERIAL PRESSURE; BINDING COMPETITION; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; DRUG BINDING SITE; DRUG EFFECT; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; EXPERIMENTAL ANIMAL; FLUORESCENCE ANALYSIS; GOOD LABORATORY PRACTICE; HEART LEFT VENTRICLE; HEART MUSCLE POTENTIAL; HEART PAPILLARY MUSCLE; HEART RATE; HEART REPOLARIZATION; HEMODYNAMICS; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; IN VITRO STUDY; ISOLATED HEART; ISOTOPE LABELING; NONHUMAN; PATCH CLAMP; PATIENT SAFETY; PURKINJE FIBER; QT INTERVAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; TELEMETRY; TOXICITY TESTING; VOLTAGE CLAMP; XENOPUS; ACTION POTENTIAL; ANIMAL; ANIMAL MODEL; CARDIOVASCULAR DISEASE; CELL MEMBRANE POTENTIAL; CHEMICALLY INDUCED DISORDER; CYTOLOGY; GENETICS; HEART MUSCLE CONDUCTION SYSTEM; HEART VENTRICLE; METABOLISM; METHODOLOGY; PRACTICE GUIDELINE;

ACTION POTENTIALS; ANIMALS; CARDIOVASCULAR DISEASES; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; GUIDELINES; HEART CONDUCTION SYSTEM; HEART VENTRICLES; HUMANS; MEMBRANE POTENTIALS; MODELS, ANIMAL; PATCH-CLAMP TECHNIQUES; RISK ASSESSMENT;

EID: 34347263808     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfm026     Document Type: Review

References (78)

1. Adamantidis, M. M., Dumotier, B. M., and Caron, J. F. (1998). Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Fundam. Clin. Pharmacol. 12, 70-76.
2. Adamantidis, M. M., Lacroix, D. L., Caron, J. F., and Dupuis, B. A. (1995). Electrophysiological and arrhythmogenic effects of the histamine type 1-receptor antagonist astemizole on rabbit Purkinje fibers: clinical relevance. J. Cardiovasc. Pharmacol. 26, 319-327.
3. Anonymous. (1995). Japanese Guidelines for Nonclinical Studies of Drugs Manual 1995. Yakuji Nippo Limited, Tokyo, Japan.
4. Anonymous. (1997). Committee for Proprietary Medicinal Product. Points to Consider. The Assessment of QT Interval Prolongation by Non-Cardiovascular Medicinal Products. CPMP/986/96.
5. Anonymous. (2001). ICH Harmonized Tripartite Guideline, S7A Safety Pharmacology Studies for Human Pharmaceuticals. U.S. Department of Health and Human Services, FDA. Available at: http://www.fda.gov/cder/ guidance/P266_27807. Accessed July 2001.
6. Anonymous (2004). ICH S7B Guideline Step 2 Revision. The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. U.S. Department of Health and Human Services, FDA. Available at: http://www.fda.gov/cder/ guidance/5533drf.htm. Accessed 10 June 2004.
7. Antzelevitch, C., Sun, Z.-Q., Zhan, Z.-Q., and Yan, G.-X. (1996). Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de Pointes. J. Am. Coll. Cardiol. 28, 1836-1848.
8. Antzelevitch, C., Shimizu, W., Yan, G.-X., Sicouri, S., Weissenburger, J., Nesterenko, V. V., Burasnikov, A., Diego, J. D., Saffitz, J., and Thomas, G. P. (1999). The M cell: Its contribution to the ECG and to normal and abnormal electrical function of the heart. J. Cardiovasc. Electrophysiol. 10, 1124-1152.
9. Arcangeli, A., Rosati, B., Cherubini, A., Crociani, O., Fontana, L., Passani, B., Wanke, E., and Olivotto, M. (1998). Long term exposure to retinoic acid induced the expression of IRK1 channels in HERG channel-endowed neuroblastoma cells. Biochem. Biophys. Res. Commun. 244, 706-711.
10. Aronov, A. M. (2006) Common pharmacophores for uncharged human ethera- go-go-related gene (hERG) blockers. J. Med. Chem. 49, 6917-6921.
11. Bachmann, A., Mueller, S., Kopp, K., Brueggemann, A., Suessbrich, H., Gerlach, U., and Busch, A. E. (2002). Inhibition of cardiac potassium currents by pentobarbital. Naunyn Schmiedeberg Arch. Pharmacol. 365, 29-37.
12. Baxter, D. F., Kirk, M., Garcia, A. F., Raimondi, A., Holmqvist, M. H., Flint, K. K., Bojanic, D., Distefano, P. S., Curtis, R., and Xie, Y. (2002). A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channels. J. Biomol. Screen. 7, 79-85.
13. Ks channels by the chromanol 293B. Pflügers Arch. 432, 1094-1096.
14. Carlsson, L., Amis, G. J., Andersson, B., Drews, L., Duker, G., and Wadstedt, G. (1997). Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro implications for proarrhythmic potential? J. Pharmacol. Exp. Ther. 282, 220-227.
15. Cavero, I., Mestre, M., Guillon, J. M., Heuilett, E., and Roach, A. G. (1999). Preclinical in vitro cardiac electrophysiology: A method of predicting arrhythmogenic potential of antihistamines in humans? Drug Saf. 21(Suppl 1), 19-31.
16. Champeroux, P., Martel, E., Vannier, C., Blanc, V., Leguennec, J. Y., Fowler, J., and Richard, S. (2000). The preclinical assessment of the risk for QT interval prolongation. Thérapie 55, 101-109.
17. Cheng, C. S., Alderman, D., Kwash, J., Dessaint, J., Patel, R., Lescoe, M. D., Kinrade, M. B., and Yu, W. (2002). A high-throughput HERG potassium channel function assay: An old assay with a new look. Drug Dev. Ind. Pharm. 28, 177-191.
18. Deveney, A. M., Kjellström, A., Forsberg, T., and Jackson, D. M. (1998). A pharmacological validation of radiotelemetry in conscious, freely moving rats. J. Pharmacol. Toxicol. Methods 40, 71-79.
19. Drolet, B., Vincent, F., Rail, J., Chahine, M., Deschenes, D., Nadeau, S., Kalifa, M., Hamelin, B. A., and Turgeon, J. (1999). Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J. Pharmacol. Exp. Ther. 288, 1261-1268.
20. Dumotier, B. M., Adamantidis, M. M., Puisieux, F. L., Bastide, M. M., and Dupuis, B. A. (1999). Repercussions of pharmacologic reduction in ionic currents on action potential configuration in rabbit Purkinje fibers: Are they indicative of proarrhythmic potential? Drug Dev. Res. 47, 83-76.
21. Eckardt, L., Haverkamp,W.,Mertens,H., Johna, R., Clague, J. R., Borggrefe, M., and Breithart, G. (1998). Drug-related torsades de pointes in the isolated rabbit heart: Comparison of clofilium, d,l-sotalol, and erythromycin. J. Cardiovasc. Pharmacol. 32, 425-434.
22. 4(3)) in model systems and cells. Chem. Phys. Lipids 69, 137-150.
23. Finlayson, K., Pennington, A. J., and Kelly, J. S. (2001b). [3H]Dofetilide binding in SHSY5Y and HEK 293 cells expressing a HERG-like K+ channel? Eur. J. Pharmacol. 412, 202-212.
24. Finlayson, K., Turnbull, L., January, C. T., Sharkey, J., and Kelly, J. S. (2001a). [3H]Dofetilide binding to HERG transfected membranes: A potential high throughput preclinical screen. Eur. J. Pharmacol. 430, 147-148.
25. Fossa, A. A., Wisialowski, T., Magnano, A., Eric, W., Winslow, R., Gorczyca, W., Crimin, K., and Raunig, D. L. (2005). Dynamic beat-to-beat modeling of the QT-RR interval relationship: Analysis fof QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J. Pharmacol. Exp. Ther. 312 1-11.
26. Franz, M. R. (1991). Method and theory of monophasic action potential recording. Prog. Cardiovasc. Dis. 6, 347-368.
27. Gintant, G. A., Limberis, J. T., McDermott, J. S.,Wegner, C. D., and Cox, B. F. (2001). The canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J. Cardiovasc. Pharmacol. 37, 607-618.
28. Gonzalez, J. E., and Maher, M. P. (2002). Cellular fluorescent indicators and voltage/ion probe reader (VIPR™): Tools for ion channel and receptor drug discovery. Recept. Channels 8, 283-295.
29. Guth, B. D., Germeyer, S., Kolb, W., and Markert, M. (2004). Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. J. Pharmacol. Toxicol. Methods 49, 159-169.
30. Hamlin, R. L., Kijtawornrat, A., and Keene, B. W. (2004). How many cardiac cycles must be measured to permit accurate RR, QT, and QTc estimates in conscious dogs? J. Pharmacol. Toxicol. Methods 50 103-108.
31. Hamlin, R. L., Kijtawornrat, A., Keene, B. W., and Hamlin, D. M. (2003). QT and RR intervals in conscious and anesthetized guinea pigs with highly varying RR intervals and given QTc-lengthening test articles. Toxicol. Sci. 76, 437-442.
32. Hauser, D., Stade, M., Schmidt, A., and Hanauer, G. (2005). Cardiovascular parameters in anaesthetized guinea pigs: A safety pharmacology screening model. J. Pharmacol. Toxicol. Methods 52 106-114.
33. Haverkamp, W., Breithardt, G., Camm, A. J., Janse, M. J., Rosen, M. R., Antzelevitch, C., Escande, D., Franz, M., Malik, M., Moss, A., et al. (2000). The potential for QT prolongation and pro-arrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications report on a policy conference of the European society of cardiology. Cardiovasc. Res. 47, 219-233.
34. Hayashi, S., Yoshihide, K., Tabo, M., Fukuda, H., Itoh, T., Shimosato, T., Amano, H., Saito, M., Morimoto, H., Yamada, K., et al. (2005). QT PRODACT: A multi-site study of in vitro action potential assays on 21 compounds in isolated guinea-pig papillary muscles. J. Pharmacol. Sci. 99, 423-437.
35. Herron, W., Towers, C., and Templeton, A. (2004). Experiences in method development for the analysis of in vitro study solutions for content. J. Pharmacol. Toxicol. Methods 49, 211-216.
36. Hey, J. A., del Prado, M., Kreutner,W., and Egan, R.W. (1996) Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in an experimental model of torsade de pointes. Arzneimforsch/Drug Res. 46, 159-163.
37. Jamieson, C., Moir, E. M., Rankovic, Z., and Wishart, G. (2006). Medicinal chemistry of hERG optimizations: Highlights and hang-ups. J. Med. Chem. 49, 5029-5046.
38. Johna, R., Mertens, H., Haverkamp, W., Eckardt, L., Niederbröcker, T., Borggrefe, M., and Breithardt, G. (1998). Clofilium in the isolated perfused rabbit heart: A new model to study proarrhythmia by class III antiarrhythmic drugs. Basic Res. Cardiol. 93, 127-135.
39. + current by dofetilide. Circ. Res. 72, 75-83.
40. Kalifa, M., Drolet, B., Daleau, P., Lefez, C., Gilbert, M., Plante, S., O'Hara, G. E., Gleeton, O., Hamelin, B. A., and Turgeon, J. (1999). Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 antagonist diphenhydramine. J. Pharmacol. Exp. Ther. 288, 858-865.
41. Kiss, L., Bennett, P. B., Uebele, V. N., Koblan, K. S., Kane, S. A., Neagle, B., and Schroder, K. (2003). High throughput ion-channel pharmacology: Planar-array-based voltage clamp. Assay Drug Dev. Technol. 1, 127-135.
42. Klumpp, A., Trautmann, T., Markert, M., and Guth, B. (2006). Optimizing the experimental environment for dog telemetry studies. J. Pharmacol. Toxicol. Methods 54, 141-149.
43. Lacroix, P., and Provost, D. (2000). Basic safety pharmacology: The cardiovascular system. Thérapie 55, 63-69.
44. Liem, L. K. Simard, J. M., Song, Y., and Tewari, K. (1995). The patch clamp technique. Neurosurgery 36, 382-392.
45. Markert, M., Klumpp, A., Trautmann, T., and Guth, B. D. (2004). A novel propellant-free inhalation drug delivery system for cardiovascular safety pharmacology evaluations in dogs. J Pharmacol. Toxicol. Methods 50, 109-199.
46. Mellor, P. M., and Pettinger, S. J. (1986). Application of radio telemetry to cardiovascular monitoring in unrestrained animals. J. Pharmacol. Methods 16, 181-184.
47. Meyners, M., and Markert, M. (2004). Correcting the QT interval for changes in HR in pre-clinical durg development. J. Pharmacol. Toxicol. Methods 50, 109-119.
48. Morganroth, J., Anderson, J. L., and Gentzkow, G. D. (1986) Classification by type of ventricular arrhythmias predicts frequency of adverse cardiac events from flecainide. J. Am. Coll. Cardiol. 8 607-615.
49. Neher, E., and Sakmann, B. (1976). Single-channel currents recorded from membranes of denervated frog muscle fibres. Nature 260, 799-802.
50. Netzer, R., Bischoff, U., and Ebneth, A. (2003). HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Curr. Opin. Drug Discov. Dev. 6, 462-469.
51. Netzer, R., Ebneth, A., Bischoff, U., and Pongs, O. (2001). Screening lead compounds for QT interval prolongation. Drug Discov. Today 6, 78-84.
52. Pestel, S., Martin, H.-J., Maier, G.-M., and Guth, B. (2006). Effect of commonly used vehicles on gastrointestinal, renal, and liver function in rats. J Pharmacol. Toxicol. Methods 54, 200-214.
53. Plasek, J., and Sigler, K. (1996). Slow fluorescent indicators of membrane potential: A survey of different approaches to probe response analysis. J. Photochem. Photobiol. B Biol. 33, 101-124.
54. Po, S. S.,Wang, D.W., Zang, I. C. H., Johnson, J. P., Nie, L., and Bennett, P. B. (1999). Modulation of hERG potassium channels by extracellular magnesium and quinidine. J. Cardiovasc. Pharmacol. 33, 181-185.
55. Price, D. A., Armour, D., De Groot, M., Lieshman, D., Napier, C., Perros, M., Stammen, B. L., and Wood, A. (2006). Overcoming HERG affinity in the discovery of the CCR5 antagonist maraviroc. Bioorg. Med. Chem. Lett. 16, 4633-4637.
56. Provan, G., Stanton, A., Sutton, A., Rankin-Burkart, A., and Laycock, S. K. (2005). Development of a surgical approach for telemetering guinea pigs as a model for screening QT interval effects. J. Pharmacol. Toxicol. Methods 52, 223-228.
57. Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K. S., Strang, I., Sullivan, A. T., Wallis, R., Camm, A. J., et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58, 32-45.
58. Redfern,W. S.,Wakefield, I. D., Prior, H., Pollard, C. E., Hammond, T. G., and Valentin, J.-P. (2002). Safety pharmacology - a progressive approach. Fundam. Clin. Pharmacol. 16, 161-173.
59. Salata, J. J., Jurkiewicz, N. K., Wallace, A. A., Stupineski, R. F., III, Guinosso, P. J., Jr, and Lynch, J. J., Jr. (1995). Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine. Circ. Res. 76, 110-119.
60. + currents: Differential sensitivity to block by class III antiarrhythmic agents. J. Gen. Physiol. 96 195-215.
61. Sanguinetti, M. C., and Mitcheson, J. S. (2005). Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 26, 119-124.
62. Schierok, H., Markert, M., Pairet, M., and Guth, B. (2000). Continuous assessment of multiple vital physiological functions in conscious freely moving rats using telemetry and a plethysmography system. J. Pharmacol. Toxicol. Methods 43, 211-217.
63. Schroeder, K., Neagle, B., Trezise, D. J., and Worley, J. (2003). IonWorks™ HT: A new high-throughput electrophysiology measurement platform. J. Biomol. Screen. 8, 50-64.
64. Snyders, D. J., and Chaudhary, A. (1996). High affinity open channels blockade by dofetilide of HERG expressed in a human cell line. Mol. Pharmacol. 49, 949-955.
65. Stark, G., Stark, U., and Tritthart, H. A. (1987). Continuous ECG measurements of intracardiac activity from the surface of Landorff-perfused guinea pig hearts. Basic Res. Cardiol. 83, 202-212.
66. Tang,W., Kang, J.,Wu, X., Rampe, D.,Wang, L., Shen, H., Li, Z., Dunnington, D., and Garyantes, T. (2001). Development and evaluation of high throughput functional assay method for HERG potassium channel. J. Biomol. Screen. 6, 325-331.
67. Tashibu, H., Myazaki, H., Aoki, K., Akie, Y., and Yamamoto, K. (2005). QT PRODACT: In vivo QT assay in anesthetized dog for detecting the potential for QT interval prolongation by human pharmaceuticals. J. Pharm. Sci. 99, 473-486.
68. Terstappen, G. C. (1999). Functional analysis of native and recombinant ion channels using a high-capacity nonradioactive rubidium efflux assay. Anal. Biochem. 272, 149-155.
69. Teschemacher, A. G., Seward, E. P., Hancox, J. C., and Witchel, H. J. (1999). Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br. J. Pharmacol. 128, 479-485.
70. + channels: Friend and foe. Trends Pharmacol. Sci. 22, 240-246.
71. Wang, J., Della Penna, K., Wang, H., Karczewski, J., Connolly, T. M., Koblan, K. S., Bennett, P. B., and Salata, J. J. (2003). Functional and pharmacological properties of canine ERG potassium channels. Am. J. Physiol. Heart Circ. Physiol. 284, H256-H267.
72. Weerapura, M., Nattel, S., Chartier, D., Caballero, R., and Hebert, T. E. (2002). A comparison of current carried by hERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? J. Physiol. 540, 15-27.
73. 86Rb efflux in rat blood vessels. Br. J. Pharmacol. 88, 121-128.
74. Weissenburger, J., Nesterenko, V. V., and Antzelevitch, C. (2000). Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: Torsades de pointes develops with halothane but not pentobarbital anesthesia. J. Cardiovasc. Electrophysiol. 11, 290-304.
75. Wible, B. A., Hawryluk, P., Ficker, E., Kuryshev, Y. A., Kirsch, G., and Brown, A. M. (2005). HERG-Lite®: Novel comprehensive high-throughput screen for drug-induced HERG risk. J. Pharmacol. Toxicol. Methods 52, 136-145.
76. Witchell, H. J., Milnes, J. T., Mitcheson, J. S., and Hancox, J. C. (2002). Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. J. Pharmacol. Toxicol. Methods 48 65-80.
77. Yuill, K. H., Borg, J. J., Ridley, J. M., Milnes, J. T., Witchel, H. J., Paul, A. A., Kozlowski, R. Z., and Hancox, J. C. (2004). Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphenewithout QT interval prolongation. Biochem. Biophys. Res. Commun. 318, 556-561.
78. Zbinden, G. (1984). Neglect of function and obsession with structure in toxicity testing. In Proceedings, 9th International Congress of Pharmacology, Vo1. 43-49. Macmillan, New York.